Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 111 posts found.

abbvie_0

AbbVie and Eisai celebrate approval of new Humira indication

September 28, 2016
Research and Development, Sales and Marketing AbbVie, Eisai, Humira

AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …

News
eisa0001

EU approval for Eisai kidney cancer treatment

September 15, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus

The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …

News
eisa0008

Eisai reveals new long-term seizure control data at ECE 2016

September 13, 2016
Manufacturing and Production, Research and Development Eisai, epilepsy

Eisai has revealed new data on long-term seizure control in different seizure types at the 12th European Congress on Epileptology …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 9, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis

It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …

News
iqwigsmall

Eisai “cannot understand” German agency’s recommendation to reject Halaven

September 6, 2016
Manufacturing and Production, Research and Development Eisai, Germany, Halaven, IQWIG, german

Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …

News
eisa0002

Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England

August 2, 2016
Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer

Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …

News
ema_inside

EMA recommends two new treatments for advanced kidney cancer

July 22, 2016
Research and Development, Sales and Marketing EMA, Eisai, renal cell carcinoma

The European Medicines Agency (EMA) has recommended two new medicines for the treatment of advanced renal cell carcinoma, or kidney …

News

Eisai criticises NICE and CDF for rare cancer ‘black hole’ in England

July 8, 2016
Medical Communications, Research and Development CDF, Eisai, NICE, black hole

Japanese pharmaceutical company Eisai (TYO: 4523) has issued a statement expressing its dismay that advanced thyroid cancer patients in England …

News
eisa0005

Eisai launches cancer drug Lenvatinib in Mexico

July 4, 2016
Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch

Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …

News
lab

Eisai partners with Novartis in renal cell carcinoma collaboration

June 3, 2016
Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate

Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …

News
trials

Eisai granted additional indication for Lenvima in renal cell carcinoma

May 16, 2016
Sales and Marketing Eisai, additional indication, renal cell carcinoma

Eisai has announced that it has received approval from the US Food and Drug Administration (FDA) for an additional indication …

News
2174264_eisai_logo-web

Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe

May 5, 2016
Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma

The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …

News
hawthorn_eisai

Eisai poaches senior Pfizer and Sanofi execs for neurology group

April 26, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim

Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …

Appointment
halaven

Eisai’s Halaven recommended for European approval

April 4, 2016
Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma

Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …

News
ea_pharma

Eisai announces agreement to set up new gastrointestinal speciality company

March 30, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality

Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023